Quarterly ResultMay 13, 2026, 07:08 AM
PDS Biotech Reports Q1 2026 Results; Advances Clinical Programs
AI Summary
PDS Biotechnology reported a reduced net loss of $7.3 million for Q1 2026, down from $8.5 million in Q1 2025. The company made significant clinical and regulatory progress, including amending the VERSATILE-003 Phase 3 trial protocol for potential accelerated approval and completing enrollment in the metastatic colorectal cancer trial for PDS01ADC. Positive clinical and immunological biomarker data for PDS01ADC in mCRC and encouraging early results in mCRPC were also published and presented, alongside new patent grants for PDS0101.
Key Highlights
- Amended VERSATILE-003 Phase 3 trial protocol to include progression-free survival (PFS) as an interim primary endpoint for potential accelerated approval.
- Completed enrollment in the metastatic colorectal cancer trial for PDS01ADC.
- PDS01ADC showed 77.8% objective response rate (ORR) in mCRC at six months, with 85% 24-month survival rate.
- PDS01ADC demonstrated median PFS of 9.6 months in metastatic castration-resistant prostate cancer (mCRPC).
- Granted new patents for PDS0101 in the U.S. and Japan, extending market protection into the 2040s.
- Reported Q1 2026 net loss of $7.3 million, or $0.13 per share, compared to $8.5 million, or $0.21 per share in Q1 2025.
- Research and development expenses decreased to $3.5 million in Q1 2026 from $5.8 million in Q1 2025.
- Cash balance as of March 31, 2026, was $21.7 million.
Price Impact
More from PDSB